Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

DiaMedica Therapeutics (DMAC) Liabilities and Shareholders Equity (2018 - 2019)

Historic Liabilities and Shareholders Equity for DiaMedica Therapeutics (DMAC) over the last 2 years, with Q3 2019 value amounting to $11.0 million.

  • DiaMedica Therapeutics' Liabilities and Shareholders Equity changed N/A to $11.0 million in Q3 2019 from the same period last year, while for Dec 2019 it was $39.3 million, marking a year-over-year increase of 11446.1%. This contributed to the annual value of $18.3 million for FY2018, which is N/A changed from last year.
  • Latest data reveals that DiaMedica Therapeutics reported Liabilities and Shareholders Equity of $11.0 million as of Q3 2019.
  • DiaMedica Therapeutics' 5-year Liabilities and Shareholders Equity high stood at $18.3 million for Q4 2018, and its period low was $11.0 million during Q3 2019.